Zhengnian Li

Zhengnian Li

Auto-generated profile, based on publicly available information

Zhengnian Li

Department of Chemical and Systems Biology, ChEM-H, Stanford Cancer Institute, School of Medicine, Stanford University, Stanford, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2019 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
TFTyler B. Faust
Tyler B. Faust
HYHojong Yoon
Hojong Yoon
RNRadosław P. Nowak
Radosław P. Nowak
KDKatherine A. Donovan
Katherine A. Donovan
ZLZhengnian Li
Zhengnian Li
EFEric S. Fischer
Eric S. Fischer

28 February 2019 in Blood
Verified
Journal Article
Closed access
PDF file
DDDennis Dobrovolsky
Dennis Dobrovolsky
EWEric S. Wang
Eric S. Wang
SMSara Morrow
Sara Morrow
CLCatharine Leahy
Catharine Leahy
TFTyler Faust
Tyler Faust
NGNathanael S. Gray
Nathanael S. Gray
The covalent Bruton tyrosine kinase (BTK) inhibitor ibrutinib is highly efficacious against multiple B-cell malignancies. However, it is not selective for BTK, and multiple mechanisms of resistance, including the C481S-BTK mutation, can compromise its efficacy. We hypothesized that small-molecule–induced BTK degradation may overcome some of the limitations of traditional enzymatic inhibitors. Here, we demonstrate that BTK degradation results in potent suppression of signaling and proliferation in cancer cells and that BTK degraders efficiently degrade C481S-BTK. Moreover, we discovered DD-03-171, an optimized lead compound that exhibits enhanced antiproliferative effects on mantle cell lymphoma (MCL) cells in vitro by degrading BTK, IKFZ1, and IKFZ3 as well as efficacy against patient-derived xenografts in vivo. Thus, “triple degradation” may be an effective therapeutic approach for treating MCL and overcoming ibrutinib resistance, thereby addressing a major unmet need in the treatment of MCL and other B-cell lymphomas.

1 January 2020 in Cell Chemical Biology
Verified
Journal Article
Closed access
ZLZhengnian Li
Zhengnian Li
BPBenika J. Pinch
Benika J. Pinch
COCalla M. Olson
Calla M. Olson
KDKatherine A. Donovan
Katherine A. Donovan
RNRadosław P. Nowak
Radosław P. Nowak
NGNathanael S. Gray
Nathanael S. Gray

5 November 2024 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
HRHlib Razumkov
Hlib Razumkov
ZJZixuan Jiang
Zixuan Jiang
KBKheewoong Baek
Kheewoong Baek
IYInchul You
Inchul You
QGQixiang Geng
Qixiang Geng
NGNathanael S. Gray
Nathanael S. Gray

1 April 2022 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
TGThomas W. Gero
Thomas W. Gero
DHDavid E. Heppner
David E. Heppner
TBTyler S. Beyett
Tyler S. Beyett
CTCiric To
Ciric To
SASeth C. Azevedo
Seth C. Azevedo
DSDavid A. Scott
David A. Scott

1 April 2019 in Antiviral Research
Verified
Journal Article
Closed access
JPJared Pitts
Jared Pitts
CHChih-Yun Hsia
Chih-Yun Hsia
WLWenlong Lian
Wenlong Lian
JWJinhua Wang
Jinhua Wang
MPMarc-Philipp Pfeil
Marc-Philipp Pfeil
PYPriscilla L. Yang
Priscilla L. Yang